Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: ROIV stock price vs LRCX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at LRCX's multiple
Needs LRCX P/S.
Implied fair value · at ROIV's multiple
Needs ROIV P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ROIV FY 2026 (ended Mar 31, 2026) · LRCX FY 2026 (ended Jun 28, 2026). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
ROIVANT SCIENCES LTD. · implied price per share
Bear
$4.51
Base
$5.30
Bull
$6.10
LAM RESEARCH CORPORATION · implied price per share
Bear
$55.13
Base
$64.85
Bull
$74.58
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.10x
0.30x
Net debt / EBITDA
Leverage against operating earnings
32.78x
-0.49x
Cash and equivalents
Liquid reserves on the balance sheet
$4.29B
$8.15B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Revolution Medicines, Inc.
ROIV vs RVMD
INCYTE CORP
ROIV vs INCY
Sarepta Therapeutics, Inc.
ROIV vs SRPT
EXELIXIS, INC.
ROIV vs EXEL
VERTEX PHARMACEUTICALS INC / MA
ROIV vs VRTX
Applied Materials, Inc.
ROIV vs AMAT
KLA CORP
ROIV vs KLAC
ASML HOLDING NV
ROIV vs ASML
TERADYNE, INC
ROIV vs TER
ENTEGRIS INC
ROIV vs ENTG
$442.59M
$3.72B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
Live quote
